Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
نویسندگان
چکیده
منابع مشابه
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
BACKGROUND Ruxolitinib, a Janus kinase 1 and 2 inhibitor, demonstrated improvements in spleen volume, symptoms, and survival over placebo and best available therapy in intermediate-2 or high-risk myelofibrosis patients with baseline platelet counts ≥100 × 109/L in phase III studies. The most common adverse events were dose-dependent anemia and thrombocytopenia, which were anticipated because th...
متن کاملRuxolitinib for myelofibrosis
The aim of the present study was to assess the beneficial and harmful effects of ruxolitinib in patients with myelofibrosis (MF). The Cochrane databases, PubMed and Embase were searched for studies published up to October 2012. Randomised controlled trials assessing ruxolitinib versus a placebo or the best available therapy in patients with MF were included. Two trials randomised 528 patients w...
متن کاملDoes ruxolitinib prolong the survival of patients with myelofibrosis?
A 73-year-old man was diagnosed with primary myelofibrosis (PMF) after the incidental discovery of abnormalities in a blood test performed for the control of diabetesmellitus. The patient was asymptomatic. The spleen was palpable at 6 cm below the left costal margin. Hemoglobin was 10.9 g/dL; white blood cell count was 13.2 3 10/L, with a leukoerythroblastic blood picture and 2%blasts, platelet...
متن کاملManagement of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes
PURPOSE Ruxolitinib is an oral Janus kinase (JAK) 1/JAK2 inhibitor approved in the US for the treatment of intermediate-or high-risk myelofibrosis (MF). Because thrombopoietin and erythropoietin signal through JAK2, dose-dependent cytopenias are expected with treatment. In the COMFORT-I (COntrolled Myelofibrosis study with ORal JAK inhibitor Treatment I) trial, these cytopenias were effectively...
متن کاملRuxolitinib for myelofibrosis
Myelofibrosis (MF), a myeloproliferative neoplasm, is a disease associated with a significant burden of symptoms, shortened survival and an array of standard treatment regimens which have historically lacked impact and efficacy. The discovery in 2005 of the highly prevalent JAK2V617F-activating tyrosine kinase mutation, strongly associated with myeloproliferative neoplasms, led to the rapid dev...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Leukemia
سال: 2015
ISSN: 0887-6924,1476-5551
DOI: 10.1038/leu.2015.310